Sign in
VACC Stock Price, Chart, Stats & News
Vaccitech plc
Save
192.73M
Market cap
–
Current P/E
–
Forward P/E
VACC chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | 0.31% |
ROA | -67.67% |
ROE | -70.57% |
D/E | 0.15x |
Interest coverage ratio | 6.75x |
VACC valuation
P/E | – |
P/S | – |
P/B | 2.73x |
P/CF | -4.22x |
P/FCF | -4.01x |
P/OCF | -4.22x |
PEG | 0.23x |
EV multiple | -18.83x |
About
Vaccitech plc is a clinical-stage biopharmaceutical company focused on developing cutting-edge T-cell immunotherapeutics and vaccines. Their mission is to treat and prevent a variety of infectious diseases and cancers. The company's therapeutic pipeline includes several programs undergoing clinical evaluation: VTP-300 is in Phase 1/2a clinical trials for chronic hepatitis B.
Similar securities
Based on sector and market capitalization
Report issue